Company: AZN
Filing Date: 2025-07-29
Form Type: 6-K
Source: 0001104659-25-071432
Chunk: 4

Company: ASTRAZENECA PLC
Filing Date: 2025-07-29
Form: 6-K
Chunk 4
---
 measures are not accounted for according to generally accepted accounting principles (GAAP) because they remove the effects of currency movements from Reported results. |

| 2. | Effective 1 January 2025, the Group has updated its presentation of Total Revenue, adding a new subtotal of Product Revenue, the sum of Product Sales and Alliance revenue. For further details, see Note 1: ‘Basis of preparation and accounting policy’ in the Notes to the Interim Financial Statements. |

| 3. | Core financial measures are adjusted to exclude certain items. The differences between Reported and Core measures are primarily due to costs relating to the amortisation of intangibles, impairments, legal settlements and restructuring charges. A full reconciliation between Reported EPS and Core EPS is provided in Table 9 in the Financial Performance section of this document. |

| 4. | The Company is unable to provide guidance on a Reported basis because it cannot reliably forecast material elements of the Reported results, including any fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions. Please refer to the cautionary statements section regarding forward-looking statements at the end of this announcement. |

| 5. | Effective 1 January 2025, the Group has updated its presentation of Gross Margin. For further details, see Note 1: ‘Basis of preparation and accounting policy’ in the Notes to the Interim Financial Statements |

| 6. | Income from disposals of assets and businesses, where the Group does not retain a significant ongoing economic interest, is recorded in Other operating income and expense in the Group’s financial statements. |

7

Revenue drivers Table 3: Product Revenue by medicine

| ​                                | ​ |       ​ | ​ |       ​ | ​ |        ​ | ​ |   ​ | ​ |       ​ | ​ |       ​ | ​ |        ​ | ​ |   ​ |
| ​                                |   | H1 2025 |   |       ​ |   | % Change |   |     |   | Q2 2025 |   |         |   | % Change |   |     |
| ​                                | ​ |      $m | ​ | % Total | ​ |   Actual | ​ | CER | ​ |      $m | ​ | % Total | ​ |   Actual | ​ | CER |
| Tagrisso                         |   |   3,488 | ​ |      12 | ​ |        9 | ​ |  10 |